Single case experimental design: a rigorous method for addressing inequity and enhancing precision within Para sport and exercise medicine research

Sean Tweedy (1,2) Iain Mayank Dutia, 1,3 John Cairney, 1,2 Emma Beckman^{1,4}

Approximately 4400 athletes from 184 nations competed in 22 sports at the 2024 Paris Paralympic Games. However, it is recognised that athletes with more severe disabilities and high support needs are under-represented in sport, and strategies to increase representation are required. Focusing on individuals with cerebral palsy (CP), we present evidence that people with high needs are support also underrepresented in Para sport and exercise medicine (P-SEM) research. We outline why single case experimental designs (SCEDs) are a rigorous and effective of addressing undermeans representation in P-SEM research.

CEREBRAL PALSY

CP is an eligible underlying health condition for 17 of the 22 Paralympic sports. It results from a non-progressive brain lesion and is defined as a heterogeneous group of permanent disorders affecting movement and posture.¹ CP

Correspondence to Dr Sean Tweedy; s.tweedy@uq.edu.au

heterogeneity is multidimensional and can be classified based on:

- Neurological subtype: Spastic CP (quadriplegia/diplegia/hemiplegia); dyskinetic; ataxic; and mixed.² Subtypes vary in severity and anatomical distribution.
- Functional effects: The Gross Motor Function Classification System (GMFCS) is the most common and has five levels: GMFCS level I (least severe) and II are able to walk independently; GMFCS IV/V use wheeled mobility and typically have high support needs (CP-HSN).

Additionally 95% of people with CP have >1 comorbidity² but CP-HSN have a greater prevalence of serious comorbidity including cortical blindness, deafness, gavage feeding and seizure disorders.³

EXERCISE TRAINING RESEARCH IN PEOPLE WITH CP

At least three major reviews have analysed randomised controlled trials (RCTs) that evaluate exercise training in people with CP and all report that CP-HSN participants are under-represented.4-6 CP-HSN constitutes approximately 30% of the CP population⁷ but < 3% of study participants in sport and leisure intervention research.⁴

Several factors may contribute to under-representation: this increased incidence of serious comorbidities increases the risk of adverse events. requiring more stringent risk management measures, and more qualified staff; low physical function leads to relatively

greater dependence on assistive tech-nology, personal support workers and supported transport, thereby increasing the time and financial costs of research⁸; and there is a lack of valid and reliable physical activity metrics in people with severe physical impairments. In addition to these practical consid-representation of CP-HSN may indicate that group-based designs such as RCTs are not appropriate n for this population. Specifically, within-population variability signarticularly high in CP-HSN due to the high incidence and severity of comorbid-ties such as intellectual disability, seizure disorders, gavage feeding, fatigue and pain. These will often require adapta-tion to training protocols and introduce variability that increases statistical error internal validity posed by such hetero-geneity. The aim of randomisation of partic-fants does not address the threat to internal validity posed by such hetero-geneity. The aim of randomisation is no intervention-related factors are distributed between groups. This makes the groups otherwise comparable, except for exposure to the intervention, permit-ing the intervention effect to be detected. However, the variations in neurological subtype and comorbidities that charac-terise CP-HSN will influence individual subtype and comorbidites are likely to interact in complex ways. For any given individual with CP-HSN, their unique mix of neurological subtype/s and comor-bidity type and severity will affect exer-rois tafficiently predictable to permit the confident recruitment of a homogeneous sample for randomisation. Therefore, it cannot be assumed that randomisation will be effective.

¹The School of Human Movement and Nutrition Sciences, The University of Queensland, Saint Lucia, Queensland, Australia

²The Queensland Centre for Olympic and Paralympic Studies, The University of Queensland - St Lucia Campus, Brisbane, Queensland, Australia ³School of Allied Health, Australian Catholic University, Banyo Campus, Brisbane, Queensland, Australia ⁴Para sport, Queensland Academy of Sport, Sunnybank, Queensland, Australia

GREATER PRECISION IS REQUIRED

The advent of precision healthcare has benefitted a range of patient groups which appear homogeneous with respect to observable signs and symptoms, but which can be divided into distinct subgroups based on differences at the genetic/molecular level (eg, people with various cancer types). This has permitted development of interventions that are more precise and effective. The use of RCTs to evaluate interventions for people with CP-HSN is the antithesis of a precision healthcare approach because it requires grouping people who are manifestly heterogeneous with respect to clinically important and observable signs and symptoms in order to achieve sufficiently large samples. Therefore, alternative research designs that facilitate precision are required.

SINGLE CASE EXPERIMENTAL DESIGNS (SCEDS)

SCEDs are study designs developed specifically to assess intervention effectiveness in populations that are highly complex and heterogeneous. In P-SEM research SCEDs involve repeated measures of the dependent variable/s (eg, strength, aerobic capacity, motor function) under different experimental conditions (eg, exercising or not exercising) within a single case (eg, a Para athlete or patient with high support needs).9 A well-designed SCED generates internally valid, high-level evidence.9 SCEDs are ideal for evaluating interventions in participants with severe impairments and high support needs because they require smaller samples than groupbased designs and therefore permit: (1) the allocation of time and expertise required to safely supervise participants with severe primary impairments and multiple comorbidities who are at increased risk of serious adverse events; (2) the provision of the personalised assistance required to mitigate the increased time cost associated with training; and (3) the methodological freedom to individualise training type, duration and intensity without compromising experimental control.

We recognise that the small sample sizes limit SCED external validity, and thus SCEDs should complement, not replace, RCTs. However, wider adoption of SCEDs and standardised, detailed clinical profiling will facilitate development of an evidence-base in an otherwise under-researched population, and ultimately permit an evidence synthesis or meta-analysis to offset the small samples in individual studies.

A recently published SCED investigated the therapeutic benefit of performancefocused swimming training in three previously inactive adolescents with CP-HSN.¹⁰ The SCED permitted: allocation of time and expertise required to assist and supervise participants with severe primary impairments and multiple comorbidities who were at increased risk of serious adverse events (eg, drowning, aspiration); provided the methodological freedom to individualise training parameters without compromising internal validity; and provided direct evidence that initial improvements in gross motor function were lost when training ceased and recovered when training resumed.¹⁰ It also permitted a 30-month follow-up evaluating participant adherence-which remained at 100%-and provided direct evidence that intervention benefits were maintained over time. It is difficult to envisage how these data and the insights they provide could be generated by an RCT.

CONCLUSIONS

SCEDs provide a rigorous and effective means of enhancing both equity and precision of P-SEM research evidence in clinically complex populations that are under represented in P-SEM research such as people with CP-HSN. Other patient groups in which SCEDs can be usefully applied to enhance equity and precision of P-SEM evidence include people with high support needs who have spinal cord injury, traumatic brain injury and multiple sclerosis.

Acknowledgements we would like to gratefully acknowledge on-going support of our partners in this work: (1) Queensland Academy of Sport; (2) Paralympics Australia; (3) Swimming Australia; (4) Sporting Hasbeens; (5) Gregory Terrace: St Joseph's College. We also gratefully acknowledge our ParaSTART participants and their families who have helped to improve our understanding and inform our approach to research.

Contributors ST is the guarantor of this work. All authors made substantial contributions to conception of the work, provided critical revisions, approved the final version and agreed to be accountable for the accuracy and integrity of the work.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests ST, JC and EB work for The University of Queensland, the Official Higher Education Partner for Paralympics Australia. EB is on secondment as Head of Parasport with the Queensland Academy of Sport and Paralympics Australia. ST is a member of the International Paralympic Committee's Classification Compliance and Oversight Committee and a member of World Para Athletics Classification Advisory Group.

Patient consent for publication Not applicable.

Ethics approval Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.



To cite Tweedy S, Dutia IM, Cairney J, *et al. Br J Sports Med* 2024;**58**:1242–1243.

Accepted 11 September 2024 Published Online First 19 September 2024

Br J Sports Med 2024;58:1242-1243. doi:10.1136/bjsports-2024-108587

ORCID iD

Sean Tweedy http://orcid.org/0000-0002-2011-3382

REFERENCES

- Rosenbaum. A report: the definition and classification of cerebral palsy April 2006. *Dev Med Child Neurol* 2007;49:8–14.
- 2 Hollung SJ, Bakken IJ, Vik T, et al. Comorbidities in cerebral palsy: a patient registry study. *Dev Med Child Neurol* 2020;62:97–103.
- 3 Shevell MI, Dagenais L, Hall N, et al. Comorbidities in cerebral palsy and their relationship to neurologic subtype and GMFCS level. *Neurology (ECronicon)* 2009;72:2090–6.
- 4 Lai B, Lee E, Kim Y, et al. Leisure-time physical activity interventions for children and adults with cerebral palsy: a scoping review. *Dev Med Child Neurol* 2021;63:162–71.
- 5 Ryan JM, Cassidy EE, Noorduyn SG, *et al*. Exercise interventions for cerebral palsy. *Cochrane Database Syst Rev* 2017;6:CD011660.
- 6 Verschuren O, Peterson MD, Balemans ACJ, et al. Exercise and physical activity recommendations for people with cerebral palsy. *Dev Med Child Neurol* 2016;58:798–808.
- 7 Reid SM, Carlin JB, Reddihough DS. Using the Gross Motor Function Classification System to describe patterns of motor severity in cerebral palsy. *Dev Med Child Neurol* 2011;53:1007–12.
- 8 Dutia I, Curran D, Donohoe A, et al. Time cost associated with sports participation for athletes with high support needs: a time-motion analysis of tasks required for para swimming. BMJ Open Sport Exerc Med 2022;8:e001418.
- 9 Tanious R, Manolov R, Onghena P, et al. Singlecase experimental designs: the importance of randomization and replication. *Nat Rev Methods Primers* 2024;4:27.
- 10 Dutia IM, Connick M, Beckman E, *et al*. The power of Para sport: the effect of performance-focused swimming training on motor function in adolescents with cerebral palsy and high support needs (GMFCS IV) - a single-case experimental design with 30-month follow-up. *Br J Sports Med* 2024;58:777–84.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies